Accessibility Menu
Verrica Pharmaceuticals Stock Quote

Verrica Pharmaceuticals (NASDAQ: VRCA)

$3.91
(-3.2%)
-0.13
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.91
Daily Change
(-3.2%) $0.13
Day's Range
$3.8 - $4.04
Previous Close
$3.91
Open
$4.03
Beta
0.82
Volume
383
Average Volume
274,405
Market Cap
36.9M
Market Cap / Employee
$3.91M
52wk Range
$3.8 - $17.38
Revenue
-
Gross Margin
0.86%
Dividend Yield
N/A
EPS
-$8.3
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Verrica Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VRCA-75.41%-95.38%-45.94%-98%
S&P+14.5%+93.32%+14.09%+141%

Verrica Pharmaceuticals Company Info

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$12.70M145.4%
Gross Profit$12.21M163.4%
Gross Margin96.11%6.6%
Market Cap$49.06M-84.1%
Market Cap / Employee$0.69M0.0%
Employees71-29.0%
Net Income$0.20M101.2%
EBITDA$1.71M111.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$15.40M-51.8%
Accounts Receivable$17.37M70.2%
Inventory2.5-6.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$25.57M-43.5%
Short Term Debt$13.32M1167.3%

Ratios

Q2 2025YOY Change
Return On Assets-106.68%45.6%
Return On Invested Capital-145.98%-59.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$10.04M38.6%
Operating Free Cash Flow-$10.04M38.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-1.94-6.52-2.19-2.81-101.37%
Price to Sales7.376.235.843.42-85.96%
Price to Tangible Book Value-19.42-9.37-41.16-26.19-101.28%
Enterprise Value to EBITDA-4.58-4.44-6.9143.19-281.75%
Return on Equity-243.3%-413.0%-2059.9%-1546.6%590.20%
Total Debt$47.11M$45.94M$42.43M$38.89M-16.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.